Capital & FinanceEvent: September 5, 2026
Sensible Biotechnologies notes that Typewriter Therapeutics has raised a $56M Series A to develop therapies based on R2 retrotransposons.
Published
Signal category
Capital & Finance
Quote
“Typewriter Therapeutics, which has raised a $56M Series A to develop therapies based on R2 retrotransposons”
— Miroslav Gasparek|Sensible Biotechnologies team
Company
Sensible Biotechnologies
Unlocking the next generation of mRNA medicines.
- Industry
- Biotechnology Research
- Company size
- 34 employees
At Sensible, we are building the best-in-class mRNA design, optimisation and manufacturing platform to unlock the era of mRNA therapeutics and design-based biology.
Founded 2021